Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
After finishing at $76.38 in the prior trading day, Apogee Therapeutics Inc (NASDAQ: APGE) closed at $75.76, down -0.81%. In other words, the price has decreased by -$0.81 from its previous closing price. On the day, 0.75 million shares were traded. APGE stock price reached its highest trading level at $77.45 during the session, while it also had its lowest trading level at $74.8901.
Ratios:
Our goal is to gain a better understanding of APGE by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 15.86 and its Current Ratio is at 15.86. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In the most recent recommendation for this company, Stephens on December 17, 2025, initiated with a Overweight rating and assigned the stock a target price of $95.
On December 10, 2025, Deutsche Bank started tracking the stock assigning a Buy rating and target price of $103.
On November 03, 2025, Craig Hallum started tracking the stock assigning a Buy rating and target price of $109.Craig Hallum initiated its Buy rating on November 03, 2025, with a $109 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 19 ’25 when Henderson Jane sold 1,500 shares for $80.00 per share. The transaction valued at 120,000 led to the insider holds 193,371 shares of the business.
JANE HENDERSON bought 1,500 shares of APGE for $116,025 on Dec 19 ’25. On Dec 10 ’25, another insider, HENDERSON MICHAEL THOMAS, who serves as the Chief Executive Officer of the company, sold 20,000 shares for $75.38 each. As a result, the insider received 1,507,657 and left with 1,212,987 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, APGE now has a Market Capitalization of 5175941120 and an Enterprise Value of 4595472896.
Stock Price History:
The Beta on a monthly basis for APGE is 1.42, which has changed by 0.61993635 over the last 52 weeks, in comparison to a change of 0.17673707 over the same period for the S&P500. Over the past 52 weeks, APGE has reached a high of $80.99, while it has fallen to a 52-week low of $26.20. The 50-Day Moving Average of the stock is 13.63%, while the 200-Day Moving Average is calculated to be 64.79%.
Shares Statistics:
The stock has traded on average 867.24K shares per day over the past 3-months and 1013330 shares per day over the last 10 days, according to various share statistics. A total of 59.32M shares are outstanding, with a floating share count of 40.33M. Insiders hold about 32.33% of the company’s shares, while institutions hold 84.46% stake in the company. Shares short for APGE as of 1765756800 were 8472837 with a Short Ratio of 9.77, compared to 1763078400 on 7931680. Therefore, it implies a Short% of Shares Outstanding of 8472837 and a Short% of Float of 22.659999.
Earnings Estimates
Currently, 10.0 analysts are dedicated to thoroughly evaluating and rating the performance of Apogee Therapeutics Inc (APGE) in the stock market.The consensus estimate for the next quarter is -$1.13, with high estimates of -$1.04 and low estimates of -$1.22.
Analysts are recommending an EPS of between -$3.89 and -$4.35 for the fiscal current year, implying an average EPS of -$4.19. EPS for the following year is -$4.97, with 11.0 analysts recommending between -$4.23 and -$5.82.
